Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free INBS Stock Alerts

Intelligent Bio Solutions (INBS) Competitors

Intelligent Bio Solutions logo
$2.35 -0.07 (-2.89%)
Closing price 06/10/2026 04:00 PM Eastern
Extended Trading
$2.51 +0.16 (+6.77%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

INBS vs. TMDIF, CODX, FEMY, LFWD, and RVP

Should you buy Intelligent Bio Solutions stock or one of its competitors? MarketBeat compares Intelligent Bio Solutions with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intelligent Bio Solutions include Titan Medical (TMDIF), Co-Diagnostics (CODX), Femasys (FEMY), Lifeward (LFWD), and Retractable Technologies (RVP). These companies are all part of the "medical equipment" industry.

How does Intelligent Bio Solutions compare to Titan Medical?

Intelligent Bio Solutions (NASDAQ:INBS) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Intelligent Bio Solutions has a beta of 4.21, meaning that its share price is 321% more volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intelligent Bio Solutions
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Titan Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 0.0% of Titan Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Intelligent Bio Solutions had 3 more articles in the media than Titan Medical. MarketBeat recorded 3 mentions for Intelligent Bio Solutions and 0 mentions for Titan Medical. Intelligent Bio Solutions' average media sentiment score of 0.97 beat Titan Medical's score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company Overall Sentiment
Intelligent Bio Solutions Positive
Titan Medical Neutral

Titan Medical has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Bio Solutions$3.05M1.84-$10.57M-$12.22N/A
Titan Medical$17.63M1.09$6.95M$0.053.37

Titan Medical has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -296.73%. Titan Medical's return on equity of -82.31% beat Intelligent Bio Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Bio Solutions-296.73% -176.09% -89.71%
Titan Medical N/A -82.31%-51.47%

Summary

Intelligent Bio Solutions and Titan Medical tied by winning 7 of the 14 factors compared between the two stocks.

How does Intelligent Bio Solutions compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Intelligent Bio Solutions had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 3 mentions for Intelligent Bio Solutions and 2 mentions for Co-Diagnostics. Intelligent Bio Solutions' average media sentiment score of 0.97 beat Co-Diagnostics' score of 0.44 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
Co-Diagnostics Neutral
Intelligent Bio Solutions Positive

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Intelligent Bio Solutions has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Co-Diagnostics$620K29.04-$46.90M-$15.77N/A
Intelligent Bio Solutions$3.05M1.84-$10.57M-$12.22N/A

Intelligent Bio Solutions has a net margin of -296.73% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat Intelligent Bio Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Co-Diagnostics-6,760.63% -164.92% -141.15%
Intelligent Bio Solutions -296.73%-176.09%-89.71%

Co-Diagnostics has a beta of 2.74, meaning that its share price is 174% more volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.21, meaning that its share price is 321% more volatile than the broader market.

Co-Diagnostics presently has a consensus target price of $67.50, indicating a potential upside of 1,283.20%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, equities analysts clearly believe Co-Diagnostics is more favorable than Intelligent Bio Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Co-Diagnostics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Intelligent Bio Solutions
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Intelligent Bio Solutions beats Co-Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Intelligent Bio Solutions compare to Femasys?

Femasys (NASDAQ:FEMY) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Intelligent Bio Solutions has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Femasys$2.29M6.24-$18.63M-$0.27N/A
Intelligent Bio Solutions$3.05M1.84-$10.57M-$12.22N/A

Femasys currently has a consensus price target of $106.67, indicating a potential upside of 2,155.11%. Given Femasys' stronger consensus rating and higher probable upside, equities analysts clearly believe Femasys is more favorable than Intelligent Bio Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Femasys
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Intelligent Bio Solutions
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Femasys had 3 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 6 mentions for Femasys and 3 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 0.97 beat Femasys' score of 0.13 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Femasys
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intelligent Bio Solutions
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Femasys has a beta of -2.23, indicating that its stock price is 323% less volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.21, indicating that its stock price is 321% more volatile than the broader market.

Intelligent Bio Solutions has a net margin of -296.73% compared to Femasys' net margin of -521.97%. Intelligent Bio Solutions' return on equity of -176.09% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Femasys-521.97% -258.08% -73.72%
Intelligent Bio Solutions -296.73%-176.09%-89.71%

65.3% of Femasys shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 7.6% of Femasys shares are owned by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Femasys beats Intelligent Bio Solutions on 9 of the 16 factors compared between the two stocks.

How does Intelligent Bio Solutions compare to Lifeward?

Lifeward (NASDAQ:LFWD) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 1.5% of Lifeward shares are owned by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lifeward presently has a consensus price target of $10.00, indicating a potential upside of 41.44%. Given Lifeward's stronger consensus rating and higher possible upside, equities research analysts plainly believe Lifeward is more favorable than Intelligent Bio Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifeward
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
Intelligent Bio Solutions
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Lifeward has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.21, suggesting that its stock price is 321% more volatile than the broader market.

In the previous week, Lifeward had 7 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 10 mentions for Lifeward and 3 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 0.97 beat Lifeward's score of 0.04 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lifeward
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intelligent Bio Solutions
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Intelligent Bio Solutions has lower revenue, but higher earnings than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifeward$20.92M0.95-$19.91M-$19.66N/A
Intelligent Bio Solutions$3.05M1.84-$10.57M-$12.22N/A

Lifeward has a net margin of -123.66% compared to Intelligent Bio Solutions' net margin of -296.73%. Intelligent Bio Solutions' return on equity of -176.09% beat Lifeward's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifeward-123.66% -243.14% -97.39%
Intelligent Bio Solutions -296.73%-176.09%-89.71%

Summary

Intelligent Bio Solutions beats Lifeward on 9 of the 16 factors compared between the two stocks.

How does Intelligent Bio Solutions compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Retractable Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.21, meaning that its share price is 321% more volatile than the broader market.

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Retractable Technologies has a net margin of -41.11% compared to Intelligent Bio Solutions' net margin of -296.73%. Retractable Technologies' return on equity of -17.15% beat Intelligent Bio Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Retractable Technologies-41.11% -17.15% -9.33%
Intelligent Bio Solutions -296.73%-176.09%-89.71%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Retractable Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Intelligent Bio Solutions
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Retractable Technologies has higher revenue and earnings than Intelligent Bio Solutions. Retractable Technologies is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Retractable Technologies$37.15M0.56-$7.01M-$0.21N/A
Intelligent Bio Solutions$3.05M1.84-$10.57M-$12.22N/A

In the previous week, Intelligent Bio Solutions had 3 more articles in the media than Retractable Technologies. MarketBeat recorded 3 mentions for Intelligent Bio Solutions and 0 mentions for Retractable Technologies. Intelligent Bio Solutions' average media sentiment score of 0.97 beat Retractable Technologies' score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
Retractable Technologies Neutral
Intelligent Bio Solutions Positive

Summary

Retractable Technologies and Intelligent Bio Solutions tied by winning 7 of the 14 factors compared between the two stocks.

Get Intelligent Bio Solutions News Delivered to You Automatically

Sign up to receive the latest news and ratings for INBS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INBS vs. The Competition

Export
MetricIntelligent Bio SolutionsMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$5.79M$8.99B$6.50B$11.95B
Dividend YieldN/A1.74%2.67%5.61%
P/E Ratio-0.1924.3924.4123.63
Price / Sales1.8418.40502.20102.41
Price / CashN/A90.8843.0554.72
Price / Book0.585.4510.306.70
Net Income-$10.57M$179.69M$3.56B$337.26M
7 Day Performance-4.47%-1.52%-2.93%-2.43%
1 Month Performance-25.16%7.26%-0.36%0.19%
1 Year Performance-88.13%0.31%20.08%23.16%

Intelligent Bio Solutions Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INBS
Intelligent Bio Solutions
1.1373 of 5 stars		$2.35
-2.9%		N/A-87.2%$5.79M$3.05MN/A10
TMDIF
Titan Medical
N/A$0.21
+11.3%		N/A-34.1%$23.48M$17.63MN/A50
CODX
Co-Diagnostics
2.0483 of 5 stars		$6.22
+0.3%		$67.50
+985.2%		-44.2%$22.85M$620KN/A100
FEMY
Femasys
2.023 of 5 stars		$0.37
-1.7%		$5.33
+1,336.4%		-70.4%$22.82M$2.29MN/A30
LFWD
Lifeward
2.7381 of 5 stars		$7.68
-3.4%		$10.00
+30.2%		-51.7%$22.38M$22.03MN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:INBS) was last updated on 6/11/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel